period circadian regulator 1Genealiases: PER · RIGUI · hPER
Q-omics provides the consensus-scored PER1 profile across patient tissues and cancer cell-line models. PER1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, PER1 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, PER1 RNA expression shows 17,131 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, BLCA, and ACC as cancer lineages where PER1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PER1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PER1 survival associations across molecular data types. PER1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (12) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PER1 RNA expression–survival associations across cancer types. High PER1 expression shows unfavorable associations in OV, STAD, ACC and COAD, but favorable associations in LIHC and KIRP. The LIHC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for PER1 RNA expression.
This table summarizes PER1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in BLCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PER1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PER1 shows lower tumor expression in BLCA, COAD, KIRP, LUAD, KICH and LUSC. The BLCA box plot shows higher PER1 RNA expression in normal versus tumor tissue (log2 FC = −3.102, t-test p < 0.001).
This table shows molecular features associated with PER1 in patient tissues and cancer cell lines. In patient samples, PER1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PER1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
